Joel Jakobsson1, Maria Bjerke1, Sara Sahebi1, Anniella Isgren1, Carl Johan Ekman2, Carl Sellgren3, Bob Olsson1, Henrik Zetterberg4, Kaj Blennow1, Erik Pålsson1, Mikael Landén5. 1. The Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. The Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 3. The Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 4. The Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and UCL Institute of Neurology, Queen Square, London, UK. 5. The Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and the Departments of Clinical Neuroscience and Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Bipolar disorder is associated with medical comorbidities that have been linked to systemic inflammatory mechanisms. There is, however, limited evidence supporting a role of neuroinflammation in bipolar disorder. Here we tested whether microglial activation and associated tissue remodelling processes are related to bipolar disorder by analyzing markers in cerebrospinal fluid (CSF) and serum from patients and healthy controls. METHODS: Serum was sampled from euthymic patients with bipolar disorder and healthy controls, and CSF was sampled from a large subset of these individuals. The levels of monocyte chemoattractant protein-1 (MCP-1), YKL-40, soluble cluster of differentiation 14 (sCD14), tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2), were measured, and we adjusted comparisons between patients and controls for confounding factors. RESULTS: We obtained serum samples from 221 patients and 112 controls and CSF samples from 125 patients and 87 controls. We found increased CSF levels of MCP-1 and YKL-40 and increased serum levels of sCD14 and YKL-40 in patients compared with controls; these differences remained after controlling for confounding factors, such as age, sex, smoking, blood-CSF barrier function, acute-phase proteins and body mass index. The CSF levels of MCP-1 and YKL-40 correlated with the serum levels, whereas the differences between patients and controls in CSF levels of MCP-1 and YKL-40 were independent of serum levels. LIMITATIONS: The cross-sectional study design precludes conclusions about causality. CONCLUSION: Our results suggest that both neuroinflammatory and systemic inflammatory processes are involved in the pathophysiology of bipolar disorder. Importantly, markers of immunological processes in the brain were independent of peripheral immunological activity.
BACKGROUND:Bipolar disorder is associated with medical comorbidities that have been linked to systemic inflammatory mechanisms. There is, however, limited evidence supporting a role of neuroinflammation in bipolar disorder. Here we tested whether microglial activation and associated tissue remodelling processes are related to bipolar disorder by analyzing markers in cerebrospinal fluid (CSF) and serum from patients and healthy controls. METHODS: Serum was sampled from euthymic patients with bipolar disorder and healthy controls, and CSF was sampled from a large subset of these individuals. The levels of monocyte chemoattractant protein-1 (MCP-1), YKL-40, soluble cluster of differentiation 14 (sCD14), tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2), were measured, and we adjusted comparisons between patients and controls for confounding factors. RESULTS: We obtained serum samples from 221 patients and 112 controls and CSF samples from 125 patients and 87 controls. We found increased CSF levels of MCP-1 and YKL-40 and increased serum levels of sCD14 and YKL-40 in patients compared with controls; these differences remained after controlling for confounding factors, such as age, sex, smoking, blood-CSF barrier function, acute-phase proteins and body mass index. The CSF levels of MCP-1 and YKL-40 correlated with the serum levels, whereas the differences between patients and controls in CSF levels of MCP-1 and YKL-40 were independent of serum levels. LIMITATIONS: The cross-sectional study design precludes conclusions about causality. CONCLUSION: Our results suggest that both neuroinflammatory and systemic inflammatory processes are involved in the pathophysiology of bipolar disorder. Importantly, markers of immunological processes in the brain were independent of peripheral immunological activity.
Authors: Arjan Malekzadeh; Vincent de Groot; Heleen Beckerman; Bob W van Oosten; Marinus A Blankenstein; Charlotte Teunissen Journal: Methods Date: 2012-03-24 Impact factor: 3.608
Authors: Roosmarijn C Drexhage; Roos C Padmos; Harm de Wit; Marjan A Versnel; Herbert Hooijkaas; Aart-Jan van der Lely; Nico van Beveren; Roel H deRijk; Dan Cohen Journal: Schizophr Res Date: 2008-05-16 Impact factor: 4.939
Authors: Sara Bromander; Rolf Anckarsäter; Marianne Kristiansson; Kaj Blennow; Henrik Zetterberg; Henrik Anckarsäter; Caroline E Wass Journal: J Neuroinflammation Date: 2012-10-24 Impact factor: 8.322
Authors: Gabriela D Colpo; Marion Leboyer; Robert Dantzer; Mahdukar H Trivedi; Antonio L Teixeira Journal: Expert Rev Neurother Date: 2017-11-27 Impact factor: 4.618
Authors: Anniella Isgren; Andreas Göteson; Jessica Holmén-Larsson; Aurimantas Pelanis; Carl Sellgren; Erik Joas; Timea Sparding; Henrik Zetterberg; Erik Smedler; Joel Jakobsson; Mikael Landén Journal: Mol Psychiatry Date: 2022-08-19 Impact factor: 13.437
Authors: Noriko Yoshimi; Takashi Futamura; Keiji Kakumoto; Alireza M Salehi; Carl M Sellgren; Jessica Holmén-Larsson; Joel Jakobsson; Erik Pålsson; Mikael Landén; Kenji Hashimoto Journal: BBA Clin Date: 2016-04-03